ArticleEXCLI journal2019
MCT4 promotes cell proliferation and invasion of castration-resistant prostate cancer PC-3 cell line.
Article in EXCLI journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- MCT4 deficiency suppresses tumor incidence and metastasis by downregulating IGF1 expression and enhancing anti-tumor immunity.Communications biology · 2026Article
- New frontiers in prostate cancer treatment from systemic therapy to targeted therapy.EMBO molecular medicine · 2025Review
- SLC16A3 (MCT4) expression in tumor immunity and Metabolism: Insights from pan-cancer analysis.Biochemistry and biophysics reports · 2025Article
- Enhancing antitumor immunity: the role of immune checkpoint inhibitors, anti-angiogenic therapy, and macrophage reprogramming.Frontiers in oncology · 2025Review
- The impact of solute carrier proteins on disrupting substance regulation in metabolic disorders: insights and clinical applications.Frontiers in pharmacology · 2024Review
- Monocarboxylate transporter 4 promotes the migration of non‑cancerous L929 fibroblast cells by activating the IGF1/IGF1R/PIK3R3/SGK1 axis.Oncology letters · 2023Article
- Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy.Acta pharmacologica Sinica · 2022Review
- Lactate Transporter SLC16A3 (MCT4) as an Onco-Immunological Biomarker Associating Tumor Microenvironment and Immune Responses in Lung Cancer.International journal of general medicine · 2022Article
- Comprehensive Analysis of the Relationship Between Metabolic Reprogramming and Immune Function in Prostate Cancer.OncoTargets and therapy · 2021Article
- Role of monocarboxylate transporters in the diagnosis, progression, prognosis, and treatment of prostate cancer.Turkish journal of urology · 2020Review
- ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Clinical Significance of CD147 in Children with Inflammatory Bowel Disease.BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is one of the leading causes of cancer-related death in men. Blocking androgen receptor (AR) signaling is an effective treatment strategy for the treatment of advanced metastatic disease of PCa in men. However, the method of blocking AR signaling is not suitable for castration-resistant prostate cancer (CRPC), and the treatment of CRPC is still clinically difficult. It has recently been reported that MCT4 is a plasma membrane transporter that mediates the secretion of lactic acid from aerobic glycolysis by cancer cells. Its expression is up-regulated in PCa and plays an important role in the carcinogenesis of PCa, but the underlying mechanism is hardly known. The MCT4 gene of PC-3 cell line was knocked down by siRNA, then MCT4 mRNA and protein was detected by real-time PCR and western blotting, respectively. CCK-8, Transwell migration assay, Flow cytometry, and TUNEL methods were used to detect the proliferation, invasion and apoptosis of PC-3 cells by MCT4 knockdown, and the expression of invasion-related proteins (MCT4) was detected by western blot analysis. The treatment of PC-3 with candidate MCT4 siRNAs led to marked inhibition of MCT4 expression in both mRNA and protein level. MCT4 knockdown inhibits PC-3 cell proliferation and facilitates apoptosis. Furthermore, MCT4 promoted the invasion capabilities of PC-3 cells by regulating invasion-related genes, such as VEGF, CD147, MMP2 and MMP9. In conclusion, MCT4 promotes oncogenic process of PCa may, as least partially, by inhibiting cell apoptosis and accelerating cell proliferation as well as invasion abilities of PC-3 cells. VEGF, CD147, MMP2 and MMP9 are important downstream genes of MCT4 in facilitating cell invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.